HR
DNTH icon

Howe & Rusling’s Dianthus Therapeutics DNTH Stock Holding History

Howe & Rusling’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4
Closed – – 1084
2022
Q1 		$0 Sell
4
-2
-33% -$109 ﹤0.01% 1021
2021
Q4 		$0 Hold
6
– – ﹤0.01% 1011
2021
Q3 		$1K Buy
6
+2
+50% +$233 ﹤0.01% 913
2021
Q2 		$1K Buy
+4
New +$735 ﹤0.01% 874

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Howe & Rusling's DNTH Position: Q2 2022 in Review

Howe & Rusling sold out of Dianthus Therapeutics (DNTH) in Q2 2022, closing a stake of 4 shares.

Howe & Rusling first reported a position in DNTH in Q2 2021 and held it in 4 quarters. The position peaked at $1K in Q3 2021. 75 funds tracked by Wall St. Rank hold DNTH as of Q2 2022.

  • Howe & Rusling reported no remaining Dianthus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Howe & Rusling sold 4 Dianthus Therapeutics shares in Q2 2022.
  • Howe & Rusling first reported a position in Dianthus Therapeutics in Q2 2021 and held it in 4 quarters.
  • Howe & Rusling's Dianthus Therapeutics position peaked at $1K in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2022.

Based on Howe & Rusling's 13F filing for Q2 2022, filed 15 Aug 2022.